Specifica Antibody Libraries and Technologies

Antibody Libraries and Technologies
by Specifica, a Q2 Solutions Company

The construction and delivery of in-vitro antibody libraries and the ability to create custom libraries from specific patient or donor populations

We are a rapidly growing antibody engineering company specializing in the creation of exceptional antibody libraries, using next-generation sequencing for quality control at all steps of construction and validation. Our patented Generation 3 Antibody Library Discovery Platform yields drug-like antibodies directly from selections, minimizing the need for downstream affinity and biophysical engineering.

Our partners are provided with exclusive libraries, each created from a unique donor diversity set not used for any other library, ensuring that each Generation 3 library is one of a kind. We also offer antibody library platforms in Fab, scFv and VHH formats, with the scFv and Fab formats also available in a fixed light chain format, and new libraries with novel formats and functionalities under development.

In addition to in-house antibody library designs, we collaborate closely with partners to create custom libraries in which essential elements are optimized according to partner needs. The power of the Generation 3 Platform may be accessed by engaging us to execute antibody discovery and optimization campaigns, or by full transfer of the platform technology. Additionally, our recently introduced AbXtract™, a powerful suite of antibody informatics tools, through its software partner OpenEye. Specifica is headquartered in Santa Fe, New Mexico.

Why Choose Specifica for your antibody needs?

Drug-like Antibodies

Antibodies selected from our libraries have high affinities and developability properties, as good as, or better, than clinical antibodies on the market, saving you time and money during development.

Antibody Discovery

We use our in-house libraries, integrated selection pipeline, next generation sequencing and AbXtract to generate unusually diverse, high affinity, drug-like developable antibodies.


60% of antibodies selected directly from our Generation 3 libraries have affinities below 10nM; 20% have affinities in the subnanomolar range; and our best affinity antibody to date is 13 pM.


After selection we use the machine learning module of AbXtract to group selected antibodies into as many as 1,000 distinctive cluster, providing antibodies against a wide variety of target epitopes.


Over 80% of antibodies from our Generation 3 Platform have no measurable biophysical liabilities, with all tested to date behaving as well as, or better, than the best therapeutic antibodies.

Full Platform Transfer

To empower discover at your site, we equip you with our integrated, state-of-the-art, antibody discovery platform, including exclusive libraries, vectors, protocols and extensive training.

Exclusive Assets

All our libraries are provided as exclusive assets, with HCDR3 donors used once and other CDRs reassembled for each library, making the antibody diversity your alone to mine, and not shared with others.

Multiple Libraries

Your exclusive HCDR3 diversity can be used to build more than one library format, providing access to different antibody functionalities.

Collaborate & Customize

In addition, to in-house designs, we create custom libraries, modifying scaffolds, tags, vectors or excluded libraries. When you need more hands, let us also conduct discovery using your exclusive library.

Straightforward Terms

Our terms eliminate complexities typically seen in platform transfers. We recognize each company is unique, and have successfully tailored structures to meet each partner’s needs.

To learn more, visit Specifica.bio